We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+28.17%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.72B
AUM Growth
+$1.22B
Cap. Flow
+$567M
Cap. Flow %
9.91%
Top 10 Hldgs %
84.78%
Holding
119
New
24
Increased
23
Reduced
25
Closed
11

Top Buys

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$22.2M
2
MDCO
Medicines Co
MDCO
+$11.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$10.9M
4
INCY icon
Incyte
INCY
+$9.54M
5
NKTR icon
Nektar Therapeutics
NKTR
+$7.71M

Top Sells

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$27M
2
ATH
Athene Holding Ltd. Class A Common Shares
ATH
+$12.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.82M
4
ZTO icon
ZTO Express
ZTO
+$6.21M
5
SAGE
Sage Therapeutics
SAGE
+$6.14M

Sector Composition

Rank Sector Weight
1 Consumer Staples 34.97%
2 Healthcare 25.04%
3 Consumer Discretionary 17.19%
4 Financials 0.66%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRMR icon
76
Larimar Therapeutics
LRMR
$377M
$3.51M 0.06%
83,333
– –
JNCE
77
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$3.51M 0.06%
250,000
-50,000
-17% -$1.07M
ALDR
78
DELISTED
Alder Biopharmaceuticals
ALDR
$3.44M 0.06%
300,000
– –
SRPT icon
79
CALL
Sarepta Therapeutics
SRPT
$1.64B
$3.37M 0.06%
100,000
-200,000
-67% -$6.51M
RGNX icon
80
Regenxbio
RGNX
$615M
$3.16M 0.06%
160,000
– –
RARE icon
81
Ultragenyx Pharmaceutical
RARE
$2.46B
$3.11M 0.05%
50,000
+20,000
+67% +$1.2M
FCX icon
82
Freeport-McMoran
FCX
$86.3B
$3M 0.05%
+250,000
New +$3.03M
ONCE
83
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$2.99M 0.05%
50,000
– –
CALA
84
DELISTED
Calithera Biosciences, Inc
CALA
$2.97M 0.05%
+10,000
New +$2.67M
GBT
85
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.73M 0.05%
100,000
-75,000
-43% -$2.23M
CMRX
86
DELISTED
Chimerix, Inc.
CMRX
$2.73M 0.05%
500,000
– –
PRQR icon
87
ProQR Therapeutics
PRQR
$246M
$2.6M 0.05%
500,000
+100,000
+25% +$497K
CLLS
88
Cellectis
CLLS
$286M
$2.58M 0.05%
100,000
-50,000
-33% -$1.19M
ALXN
89
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$2.54M 0.04%
+20,900
New +$2.43M
IMUX icon
90
Immunic
IMUX
$177M
$2.54M 0.04%
2,188
– –
NVLN
91
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$2.37M 0.04%
256,400
– –
CLVS
92
DELISTED
Clovis Oncology, Inc.
CLVS
$2.34M 0.04%
+25,000
New +$1.53M
STML
93
DELISTED
Stemline Therapeutics, Inc.
STML
$2.3M 0.04%
250,000
+150,000
+150% +$1.25M
CBIO
94
Crescent Biopharma
CBIO
$544M
$2.26M 0.04%
+2,025
New +$1.67M
NERV icon
95
Minerva Neurosciences
NERV
$191M
$2.22M 0.04%
31,413
– –
AIMT
96
DELISTED
Aimmune Therapeutics
AIMT
$2.06M 0.04%
100,000
-81,600
-45% -$1.56M
IBRX icon
97
ImmunityBio
IBRX
$7.15B
$1.71M 0.03%
225,000
– –
CLDX icon
98
Celldex Therapeutics
CLDX
$2.95B
$1.67M 0.03%
45,000
– –
CRBP icon
99
Corbus Pharmaceuticals
CRBP
$165M
$1.57M 0.03%
+8,333
New +$1.63M
JUNO
100
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.5M 0.03%
50,000
– –
1 2 3
4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2017 Portfolio in Review

As of Q2 2017, Artal Group held 119 positions worth $5.72B, up 27% from $4.51B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Artal Group deployed $567M of net new capital in Q2 2017, opening 24 new positions and adding to 23 existing holdings. Its largest new stake was Goldman Sachs: 100,000 shares worth $22.2M.

By sector, the portfolio is most concentrated in Consumer Staples at 35% of assets, down from 45% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Athene Holding Ltd. Class A Common Shares, an estimated $12.8M trimmed.

  • Artal Group's largest Q2 2017 buy was Goldman Sachs: 100,000 shares worth $22.2M.
  • Artal Group added most to Medicines Co in Q2 2017, an estimated $11.1M increase.
  • Artal Group's biggest Q2 2017 reduction was Athene Holding Ltd. Class A Common Shares, cutting an estimated $12.8M.
  • Artal Group fully exited Alibaba in Q2 2017, selling an estimated $27M.
  • Artal Group's ten largest holdings make up 85% of its $5.72B portfolio in Q2 2017.
  • Artal Group opened 24 new positions and closed 11 in Q2 2017.
  • Artal Group's portfolio value rose 27% quarter-over-quarter to $5.72B.

Based on Artal Group's 13F filing for Q2 2017, filed 11 Aug 2017.